Table 1 NIH-approved clinical trials involving repurposed drugs (Metformin, Disulfiram, Chloroquine) for the treatment of GBM and other brain cancers
From: Drug repurposing for the treatment of glioblastoma multiforme
NCT Number | Title of the study | Disease | Interventions | Clinical Phase |
|---|---|---|---|---|
NCT02780024 | Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM | GBM | •Drug: Metformin | Phase 2 |
NCT03151772 | Bioavailability of Disulfiram and Metformin in Glioblastomas | GBM | •Drug: Disulfiram •Drug: Metformin | Early Phase 1 |
NCT01430351 | Phase I Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin for Post-Radiation Therapy (RT) Glioblastoma Multiforme (GBM) | Brain Cancer | •Drug: Temozolomide •Drug: Memantine •Drug: Mefloquine •Drug: Metformin | Phase 1 |
NCT02149459 | Treatment of Recurrent Brain Tumors: Metabolic Manipulation Combined With Radiotherapy | Brain Neoplasms | •Radiation: Partial brain reirradiation. •Drug: Metformin •Behavioral: low carbohydrate diet | Phase 1 |
NCT01777919 | Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiforme | GBM | •Drug: Temozolomide •Drug: Disulfiram •Drug: Copper | Phase 2 |
NCT01907165 | Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide | GBM | •Drug: Temozolomide •Drug: Disulfiram •Dietary Supplement: Copper gluconate | Early Phase 1 |
NCT02715609 | Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma | GBM | •Drug: Disulfiram •Drug: Copper Gluconate •Procedure: Surgery •Radiation: Radiation •Drug: Temozolomide | Phase 1 Phase 2 |
NCT03151772 | Bioavailability of Disulfiram and Metformin in Glioblastomas | GBM | •Drug: Disulfiram •Drug: Metformin | Early Phase 1 |
NCT03034135 | Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma | Recurrent GBM | •Drug: Disulfiram/Copper | Phase 2 |
NCT02678975 | Disulfiram in Recurrent Glioblastoma | Glioma and GBM | •Drug: Disulfiram •Dietary Supplement: Copper •Drug: Alkylating agents | Phase 2 Phase 3 |
NCT02770378 | A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma | GBM | •Drug: Temozolomide •Drug: Aprepitant •Drug: Minocycline •Drug: Disulfiram •Drug: Celecoxib •Drug: Sertraline •Drug: Captopril •Drug: Itraconazole •Drug: Ritonavir •Drug: Auranofin | Phase 1 |
NCT00224978 | Chloroquine for Treatment of Glioblastoma Multiforme | GBM | •Drug: Chloroquine | Phase 3 |
NCT02378532 | The Addition of Chloroquine to Chemoradiation for Glioblastoma | GBM | •Drug: Chloroquine •Radiation: Radiotherapy •Drug: Temozolomide | Phase 1 |
NCT02432417 | The Addition of Chloroquine to Chemoradiation for Glioblastoma | High-grade astrocytoma GBM | •Drug: Chloroquine | Phase 2 |